HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Strontium-89 for bone metastases from prostate cancer: an update].

Abstract
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
AuthorsWei-wei Zhao, Peng Xie, Hou-fu Deng
JournalZhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 16 Issue 3 Pg. 269-72 (Mar 2010) ISSN: 1009-3591 [Print] China
PMID20369560 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Strontium Radioisotopes
Topics
  • Bone Neoplasms (radiotherapy, secondary)
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms (pathology, radiotherapy)
  • Strontium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: